Hybrid Health Meeting: Open for Talk, Closed for Grant Secrets
Published Date: 7/17/2025
Notice
Summary
The National Institute on Minority Health and Health Disparities is holding a hybrid meeting on September 5, 2025, to discuss important health topics and review grant applications. The meeting is partly open to the public and partly closed to protect private info and trade secrets. This affects researchers and communities focused on minority health, with decisions that could impact funding and future projects.
Analyzed Economic Effects
5 provisions identified: 4 benefits, 1 costs, 0 mixed.
Open Session Live and Videocast
The National Advisory Council on Minority Health and Health Disparities will hold an open session on September 5, 2025 from 10:00 a.m. to 3:00 p.m. You can attend in person (space limited) or watch the open session via the NIH Videocast at http://videocast.nih.gov/ gov/.
Closed Grant Review Session
The meeting includes a closed session on September 5, 2025 from 3:05 p.m. to 4:00 p.m. to review and evaluate grant applications; this session is closed under 5 U.S.C. 552b(c)(4) and (c)(6) to protect confidential trade secrets and personal information.
How to Submit Written Comments
Any interested person may file written comments by sending a statement to the Contact Person (Paul Cotton, Ph.D.) listed in the notice. Statements should include the sender's name, address, telephone number, and business or professional affiliation when applicable.
Special Assistance for Attendees
If you plan to attend and need special assistance such as sign language interpretation or other reasonable accommodations, you should notify the Contact Person listed in the notice in advance of the September 5, 2025 meeting.
On-Campus Security and ID Rules
Visitors attending the in-person meeting on the NIH campus will be subject to security procedures: vehicle inspections for all visitor vehicles and a requirement to show one form of identification and state the purpose of the visit as described in the notice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-13367, Domestic Sugar Program-FY 2025 Reassignment of the Overall Sugar Marketing Allotment, Cane Sugar and Beet Sugar Marketing Allotments and Company Allocations and No Actions Under the Feedstock Flexibility Program
The USDA is updating sugar limits for beet and cane sugar producers for the 2025 year, covering October 2024 to September 2025. They’re also reallocating some sugar import amounts already expected. Plus, no sugar buying or selling will happen under the Feedstock Flexibility Program this year, so producers can plan ahead with confidence.
Next: 2025-13369, National Center for Advancing Translational Sciences; Notice of Closed Meeting
The National Center for Advancing Translational Sciences is holding a private meeting on August 19, 2025, to review grant applications. This meeting affects researchers seeking funding and keeps sensitive info like trade secrets and personal details safe. No public attendance is allowed, but people can send written comments before the meeting.